A Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma

Glaucoma is an irreversible condition resulting from the increase in intraocular pressure (IOP); which leads to permanent loss of vision with the destruction of retinal ganglion cells (RGCs). The IOP elevations are controlled in normal by the physiological flow of aqueous humour. A population with a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maneesha Peter, Rajitha Panonnummal
Formato:	article
Lenguaje:	EN
Publicado:	Tabriz University of Medical Sciences 2020
Materias:	glaucoma intraocular pressure aqueous humour nanoformulations Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/4866cba9126d4958a246d2eb9fd64f5b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4866cba9126d4958a246d2eb9fd64f5b
record_format	dspace
spelling	oai:doaj.org-article:4866cba9126d4958a246d2eb9fd64f5b2021-12-05T09:40:15ZA Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma2228-58812251-730810.34172/apb.2021.048https://doaj.org/article/4866cba9126d4958a246d2eb9fd64f5b2020-09-01T00:00:00Zhttps://apb.tbzmed.ac.ir/PDF/apb-11-399.pdfhttps://doaj.org/toc/2228-5881https://doaj.org/toc/2251-7308Glaucoma is an irreversible condition resulting from the increase in intraocular pressure (IOP); which leads to permanent loss of vision with the destruction of retinal ganglion cells (RGCs). The IOP elevations are controlled in normal by the physiological flow of aqueous humour. A population with age above 40 is more susceptible to glaucoma. Other factors like gender, genetics, race etc. plays major roles in the development of the disease. Current treatment methods available for the disease includes drugs come under the classes of beta receptor blockers, carbonic anhydrase inhibitors, cholinergic agonists, prostaglandins etc. N-methyl-D-aspartate (NMDA) antagonists, inducible nitric oxide synthase (iNOS) inhibition, cytoskeletal agents, Rho-kinase inhibitors etc are few novel targets sites which are in research focus for the treatment of the disease. Developments in nanomedicine are also being evaluated for their potential in treating the growing glaucomatous population. Nanosystems are suggested to avoid the difficulties in tackling the various ocular barriers to a limit, help to decrease the instillation frequency of topical medication and can provide drug delivery in a sustained or controlled manner. This review focuses on the current and emerging treatment methods for glaucoma along with some of the nanoformulations for ocular drug delivery.Maneesha PeterRajitha PanonnummalTabriz University of Medical Sciences articleglaucomaintraocular pressureaqueous humournanoformulationsTherapeutics. PharmacologyRM1-950ENAdvanced Pharmaceutical Bulletin, Vol 11, Iss 3, Pp 399-413 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	glaucoma intraocular pressure aqueous humour nanoformulations Therapeutics. Pharmacology RM1-950
spellingShingle	glaucoma intraocular pressure aqueous humour nanoformulations Therapeutics. Pharmacology RM1-950 Maneesha Peter Rajitha Panonnummal A Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma
description	Glaucoma is an irreversible condition resulting from the increase in intraocular pressure (IOP); which leads to permanent loss of vision with the destruction of retinal ganglion cells (RGCs). The IOP elevations are controlled in normal by the physiological flow of aqueous humour. A population with age above 40 is more susceptible to glaucoma. Other factors like gender, genetics, race etc. plays major roles in the development of the disease. Current treatment methods available for the disease includes drugs come under the classes of beta receptor blockers, carbonic anhydrase inhibitors, cholinergic agonists, prostaglandins etc. N-methyl-D-aspartate (NMDA) antagonists, inducible nitric oxide synthase (iNOS) inhibition, cytoskeletal agents, Rho-kinase inhibitors etc are few novel targets sites which are in research focus for the treatment of the disease. Developments in nanomedicine are also being evaluated for their potential in treating the growing glaucomatous population. Nanosystems are suggested to avoid the difficulties in tackling the various ocular barriers to a limit, help to decrease the instillation frequency of topical medication and can provide drug delivery in a sustained or controlled manner. This review focuses on the current and emerging treatment methods for glaucoma along with some of the nanoformulations for ocular drug delivery.
format	article
author	Maneesha Peter Rajitha Panonnummal
author_facet	Maneesha Peter Rajitha Panonnummal
author_sort	Maneesha Peter
title	A Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma
title_short	A Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma
title_full	A Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma
title_fullStr	A Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma
title_full_unstemmed	A Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma
title_sort	review on newer ocular drug delivery systems with an emphasis on glaucoma
publisher	Tabriz University of Medical Sciences
publishDate	2020
url	https://doaj.org/article/4866cba9126d4958a246d2eb9fd64f5b
work_keys_str_mv	AT maneeshapeter areviewonneweroculardrugdeliverysystemswithanemphasisonglaucoma AT rajithapanonnummal areviewonneweroculardrugdeliverysystemswithanemphasisonglaucoma AT maneeshapeter reviewonneweroculardrugdeliverysystemswithanemphasisonglaucoma AT rajithapanonnummal reviewonneweroculardrugdeliverysystemswithanemphasisonglaucoma
_version_	1718372552080883712

A Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma

Ejemplares similares